The Intelligent Layer Between
Chronic Disease and Care
Flaresense is building the platform that turns passive wearable data into clinical-grade disease intelligence. Flarity, our first product, starts with IBD. The architecture expands to every inflammatory condition where early detection changes outcomes.
The Problem: Medicine is Reactive
Chronic disease management operates on a broken model. Patients see doctors every 3-6 months. Between visits, clinicians are blind. Flares happen. Hospitalizations follow. Everyone loses.
The Opportunity Gap
Hundreds of millions of people wear devices that continuously capture heart rate variability, sleep patterns, temperature, and activity. This data sits unused. No platform translates it into actionable clinical intelligence that patients can share with their doctors.
Flarity closes that gap. The app works with or without an Apple Watch. For patients struggling between visits, structured reports give them something concrete to bring to their GI, replacing "I think it started a few weeks ago" with documented trends.
The Solution: Hybrid Detection
Our core innovation is combining objective wearable signals with validated clinical symptom indices in a single, clinician-interpretable risk score.
Wearable Layer
16+ physiological signals from Apple Watch, Oura, Whoop, Garmin, Fitbit
- Heart rate variability (HRV)
- Resting heart rate trends
- Sleep duration and efficiency
- Body temperature deviations
- Blood oxygen (SpO2)
- Activity and movement patterns
Symptom Layer
Validated clinical indices, not proprietary surveys
- Harvey-Bradshaw Index (HBI) for Crohn's
- Simple Clinical Colitis Activity Index (SCCAI) for UC
- Montreal Classification staging
- Medication adherence tracking
Clinical-Grade Score
A 0-7 risk score that mirrors how gastroenterologists diagnose: biomarkers plus clinical assessment.
Patient truth trumps algorithm. If someone declares an active flare, their score immediately reflects it, up to 7/7, no wearable confirmation required. The app shifts into compassionate mode: suppressed prompts, focus on recovery guidance. Built for patients, not data purity.
Why hybrid matters: Wearables alone cannot assess abdominal pain, urgency, or stool frequency. Symptoms alone rely on patient memory and miss early physiological changes. Combined assessment catches what each layer misses individually.
Defensible Moat
Flarity is not a feature. It is a platform with compounding advantages that become harder to replicate over time.
Clinical Validation
Built on peer-reviewed Mount Sinai research published in Gastroenterology, the #1 ranked GI journal. This is a credibility moat. Competitors cannot claim the same scientific foundation.
Hybrid Detection IP
Our architecture combining objective wearable signals with validated symptom indices in a single clinical-grade score is novel. No competitor has built this integration layer.
Patient-First Architecture
User-declared state always overrides algorithmic inference. A patient in crisis does not need their Watch to confirm it. The system believes them, elevates their risk score, and shifts into compassionate mode: suppressing check-in prompts and focusing on recovery support.
GI Distribution Network
Each gastroenterologist referral creates a mini-network of patients. Early GI relationships compound. As more GIs recommend Flarity, more patients join, attracting more GIs.
Data Flywheel
Each user builds a personalized baseline on their device. The longer they use Flarity, the more accurate their predictions become. Retention drives outcomes, outcomes drive referrals.
Privacy-First Architecture
All health data stays on-device. No cloud storage. No server processing. No data sharing, ever. In a market where most health apps monetize user data, Flarity's architecture makes privacy a technical guarantee, not a policy promise.
Business Model: B2B2C
Gastroenterologists recommend Flarity to patients. Patients subscribe. This creates superior unit economics compared to direct-to-consumer acquisition.
Why B2B2C Wins
- Lower CAC: GI referral versus paid advertising
- Higher trust: Doctor recommendation equals instant credibility
- Better retention: Clinical accountability drives engagement
- Network effects: More GIs means more patients means more GIs
Consumer Subscription
21-day free trial. No credit card required to start.
Future Revenue Streams
- Practice licensing: Enterprise tier for GI practices
- Payer contracts: Flare prevention reduces healthcare costs
- Pharma partnerships: Real-world medication adherence data
- Research licensing: De-identified outcomes datasets
Target Unit Economics
B2B2C model drives superior economics: GI recommendation delivers high-intent users with near-zero acquisition cost.
Market: IBD Wedge, Platform Expansion
IBD is the beachhead. The architecture we are building applies to any chronic condition where early detection changes outcomes.
The Wedge: Inflammatory Bowel Disease
IBD patients are ideal early adopters: young (diagnosis peaks 15-35), tech-savvy, motivated to avoid flares, and already wearing devices. The condition has validated clinical indices (HBI/SCCAI) and published wearable research. This is a $28B greenfield opportunity with no dominant player.
Platform Expansion
The hybrid detection architecture is condition-agnostic. The same framework that predicts IBD flares can predict:
Each expansion requires new clinical indices and condition-specific tuning, but the core platform, wearable integration, report generation, and clinician distribution, remains the same.
Total Addressable Market
Chronic disease management is a $4.5 trillion global problem. The platform that becomes the intelligent layer between patients and their care teams captures a meaningful share of that value.
Traction
iOS App
Full-featured app with Apple Health integration, symptom tracking, hybrid risk scoring, and GI-ready PDF reports.
Clinical Validation
Algorithm grounded in peer-reviewed Mount Sinai research published in Gastroenterology journal.
B2B Website
Clinician-focused site with sample reports, recommendation tools, and GI onboarding materials.
TestFlight Beta
Onboarding initial users for product feedback and iteration before public App Store launch.
GI Practice Pilots
Structured pilot programs with gastroenterology practices to validate B2B2C distribution model.
App Store Launch
Public availability on iOS with subscription billing and GI referral tracking.
Founder
Rajan Tahiliani
Founder and CEO
15 years of B2B SaaS sales leadership at high-growth companies including OneTrust, DTN, and Kobalt.io. Deep expertise in GRC and compliance, directly applicable to healthcare privacy and regulatory requirements.
Also a Crohn's patient. After an ileocecal resection in 2024, he built the tool he wished existed: continuous monitoring that speaks his gastroenterologist's language. The founder combines enterprise sales expertise with firsthand patient experience to build and distribute a clinically credible solution.
The Ask
Raising a pre-seed round to accelerate GI practice pilots, complete App Store launch, and expand the clinical team. Looking for investors who understand healthcare, platform businesses, or both.
The Opportunity
Chronic disease affects hundreds of millions of people. Management is reactive. Flares are unpredictable. Clinicians lack visibility between visits. Patients feel powerless. Payers absorb preventable costs.
Flarity is the first platform with peer-reviewed clinical validation, hybrid detection architecture, and a capital-efficient path to market. We are building the intelligent layer between chronic disease and care.
Flaresense Inc. / Toronto, Canada